Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor

Sureda, Anna; Chabannon, Christian; Masszi, Tamás; Pohlreich, David; Scheid, Christof; Thiéblemont, Catherine; Wahlin, Björn Engelbrekt; Sakellari, Ioanna; Russell, Nigel H.; Janíková, Andrea; Dąbrowska‐Iwanicka, Anna; Touzeau, Cyrille; Esquirol, Albert; Jantunen, Esa; Werf, Steffie van der; Bosman, Paul; Boumendil, Ariane; Liu, Qianying; Celanovic, Marina; Montoto, Silvia; Dreger, Peter

doi:10.1038/s41409-019-0693-z

Cited by 13 publications

(20 citation statements)

References 21 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to previous data, 25–27 PLER use did not have an impact on the patient outcomes in the present study. Only disease status at the time of auto‐SCT was predictive for both PFS and OS in multivariate analysis.…”

Section: Discussionsupporting

confidence: 65%

Mobilization characteristics, blood graft composition, and outcome in diffuse large B‐cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background Diffuse large B‐cell lymphoma (DLBCL) is a common indication for autologous stem cell transplantation (auto‐SCT). Study Design and Methods This prospective noninterventional study aimed to evaluate the impact of mobilization characteristics and graft cellular content on hematologic recovery and outcome after auto‐SCT among 68 patients with DLBCL. Results Better mobilization capacity as manifested by blood CD34+ cell count >32 × 106/L and CD34+ cell yield of the first apheresis >2.75 × 106/kg correlated with faster neutrophil (P = .005 and P = .017) and platelet (P = .002 and P < .001) recovery. A higher number of infused CD34+ cells (> 2.65 × 106/kg) was associated with better 5‐year overall survival (OS; 95% vs 67%, P = .012). The graft CD34+CD133+CD38− cell count >0.07 × 106/kg was predictive of better 5‐year OS (87% vs 63%; P = .008) and higher graft CD3+ cell count (>23.1 × 106/kg) correlated also with better 5‐year OS (80% vs 40%, P = .008). In multivariate analysis only disease status of CR I at auto‐SCT was associated with better progression‐free survival (P = .014) and OS (P = .039). Conclusion The mobilization capacity of CD34+ cells impacted on early hematologic recovery in patients with DLBCL after auto‐SCT. Higher graft CD34+ cell count and both CD34+CD133+CD38− and CD3+ cells were also associated with better OS. The effect of optimal graft cellular composition on outcome in DLBCL should be evaluated in a randomized study.

show abstract

Section: Discussionsupporting

confidence: 65%

Mobilization characteristics, blood graft composition, and outcome in diffuse large B‐cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…We chose to focus on transfusion support and relevant clinical information such as the severe toxicities or infectious complications that impact the duration of pancytopenia were not analysed. Evaluating the efficacy of transplantation was outside this study's scope, but the low transplantation-related mortality (0.4%), the duration of admission and the engraftment times were in line with those expected [4,[16][17][18].…”

Section: Discussionmentioning

confidence: 74%

“…Pre-transplant anaemia increased the time until transfusion independence for both RBC (12 [9.5-21] vs. 7 [0-11]; p < 0.001) and platelets (13 [10-20.5] vs. 11 [9][10][11][12][13][14]; p = 0.028). Similarly, pretransplant thrombocytopenia impacted both times until RBC (10 [6.5-16.5] vs. 6 [0-10]; p < 0.001) and PT (14 [11][12][13][14][15][16][17][18][19][20][21][22] vs. 10 [8-13];…”

Section: Time Until Transfusion Independencementioning

confidence: 98%

“…reflects transfusion independence analysis.Being 60 years of age or older was associated with a longer time until transfusion independence for RBC(10 [5.8-14.3] vs. 7 [0-11]; p = 0.006) and platelets (13[11][12][13][14][15][16][17][18][19] vs. 11[8][9][10][11][12][13][14]; p < 0.001).F I G U R E 1 Transfusion requirement distribution. RBC, red blood cells.Having required plerixafor also resulted in a longer time to transfusion independence for RBC(8.5 [6.3-15.8] vs. 7 [0-11.3]; p = 0.021) and platelets(13.5 [11-18.8] vs. 11[8][9][10][11][12][13][14]; p < 0.001) as well as an infused CD34 + dose <4 Â 10 6 /kg increased time of transfusion dependency for both RBC(9 [0-14] vs. 6 [0-10]; p = 0.011) and platelets (13[10][11][12][13][14][15][16][17] vs. 10 [8-13]; p < 0.001).BEAM conditioning was associated with a longer time until PT independence ( p = 0.003) but did not prolong the time until RBC transfusion independence ( p = 0.081).Having required any RBC transfusion during the 10 days before the infusion was associated with a significant delay in transfusion independence for RBC(15 [6-38] vs. 7 [0-12]; p = 0.002) and platelets (17[11][12][13][14][15][16][17][18][19]…”

mentioning

confidence: 99%

See 1 more Smart Citation

Age, CD34+ cell dose, conditioning and pre‐transplant cytopenias can help predict transfusion support in lymphoma patients undergoing autologous stem cell transplantation

Regalado‐Artamendi,

García‐Fasanella,

Medina

et al. 2023

Vox Sanguinis

Self Cite

View full text Add to dashboard Cite

Background and ObjectivesAutologous stem cell transplant (ASCT) is a widely used therapy for lymphoma patients and can nowadays be performed on an outpatient basis. This study aimed to describe transfusion support in lymphoma patients undergoing ASCT and identify increased or prolonged transfusion requirement predictors.Materials and MethodsA retrospective study of all consecutive lymphoma patients undergoing ASCT between 2010 and 2020.ResultsOut of 226 patients, 145 (64%) received red blood cell (RBC) transfusions, whereas all 226 (100%) required platelet transfusion (PT). Transfusions between Day +1 and +30 were higher in patients over 60 (2 [1–4] vs. 2 [0–2] RBC; p = 0.001 and 4 [2–8] vs. 3 [2–4] PT; p < 0.001); patients with pre‐transplant anaemia (4 [2.5–6] vs. 2 [0–2] RBC; p < 0.001 and 5 [3–9] vs. 3 [2–4] PT; p = 0.001); pre‐transplant thrombocytopenia (2 [1–4] vs. 2 [0–2] RBC; p < 0.001 and 4 [3–8.5] vs. 2 [1–3] PT; p < 0.001) or CD34+ cell dose <4 × 106/kg (2 [0–4] vs. 2 [0–2] RBC; p = 0.024 and 4 [2–6] vs. 2 [1–3.5] PT; p < 0.001). RBC transfusion independence was reached later in patients receiving carmustine, cytarabine, etoposide and melphalan (BEAM) (hazard ratio [HR] 1.6; confidence interval [CI] 1.1–2.3) and those requiring RBC before infusion and/or with pre‐transplant anaemia (HR 2.2; CI 1.4–3.4). Age above 60 (HR 1.4; CI 1.0–1.9), BEAM conditioning (HR 1.4; CI 1.0–2.0) and pre‐transplant thrombocytopenia and/or requiring PT before infusion (HR 1.8; CI 1.4–2.5) entailed longer time until PT independence.ConclusionThese four factors (age ≥60 years; BEAM conditioning, CD34+ dose <4 × 106/kg and pre‐transplant cytopenia and/or Day −10 to 0 transfusion) allowed dividing patients into three groups with significant differences between them regarding the time until transfusion independence.

show abstract

“…We included all consecutive patients with MM from the CALM study who underwent ≥1 ASCT in this cohort between 2008 and 2012. The primary outcomes of the study were previously published [ 1 , 2 ]. Here, we report the analysis of the data collected in the CALM study.…”

Section: Methodsmentioning

confidence: 99%

Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study

Waszczuk‐Gajda

Penack

Sbianchi

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

Background: The main goal of this post hoc analysis of the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study was to evaluate the rate of short- and long-term infectious and non-infectious complications occurring after ASCT in patients with multiple myeloma (MM). Methods: The analysis included all patients with MM from the CALM study who underwent ≥1 ASCT. The primary endpoint of the analysis was to determine the rate of infectious and non-infectious complications after ASCT and to compare them in three time periods: 0–100 days, 101 days–1 year, and >1 year after the first transplant. Results: The analysis included a total of 3552 patients followed up for a median of 56.7 months (range 0.4–108.1). Complication rates decreased with the time from ASCT with 24.85 cases per 100 patient-years from day 0 to 100 days after the transplant, and <2.31 cases per 100 patient-years from the 101st day. At 100 days after ASC T, 45.7% of patients had complications, with infectious events being twice as frequent as non-infectious complications. Bacterial infections (6.5 cases per 100 patient-years, 95% CI: 6.1–7.0) and gastrointestinal complications (4.7 cases per 100 patient-years, 95% CI: 4.3–5.1) were the most common early events. The pattern of complications changed with time from ASCT. The presence of complications after ASCT was not associated with overall survival. Conclusions: Our data provide a solid basis for comparing ASCT-related complications to those caused by emerging treatments in multiple myeloma, such as CAR T-cell therapy and other immunotherapies.

show abstract

Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor

Cited by 13 publications

References 21 publications

Mobilization characteristics, blood graft composition, and outcome in diffuse large B‐cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study

Mobilization characteristics, blood graft composition, and outcome in diffuse large B‐cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study

Age, CD34+ cell dose, conditioning and pre‐transplant cytopenias can help predict transfusion support in lymphoma patients undergoing autologous stem cell transplantation

Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study

Contact Info

Product

Resources

About